Age group | <65 years (n = 89) | ≥65 years (n = 76) | ||||
P+ L (n = 47) | L (n = 42) | P + L (n = 37) | L (n = 39) | |||
Median PFS (95 % CI), months | 18.8 (12.8–26.1) | 7.7 (2.8–10.9) | 26.2 (12.6–NE) | 12.9 (5.7–22.2) | ||
HR (95 % CI) | 0.315 (0.184–0.539) | 0.505 (0.269–0.948) | ||||
CBR* rate (95 % CI), % | 80.9 (66.7–90.9) | 54.8 (38.7–70.2) | 81.1 (64.8–92.0) | 61.5 (44.6–76.6) | ||
Histological type | Ductal carcinoma (n = 117) | Lobular carcinoma (n = 37) | ||||
P+ L (n = 63) | L (n = 54) | P + L (n = 18) | L (n = 19) | |||
Median PFS (95 % CI), months | 24.4 (13.1–35.3) | 11.1 (7.3–13.3) | 9.4 (7.8–18.8) | 4.8 (1.9–16.4) | ||
HR (95 % CI) | 0.393 (0.239–0.647) | 0.626 (0.282–1.391) | ||||
CBR* rate (95 % CI), % | 82.5 (70.9–90.9) | 63.0 (48.7–75.7) | 72.2 (46.5–90.3) | 42.1 (20.3–66.5) | ||
Prior systemic treatment | None (n = 81) | Yes (n = 84) | ||||
P + L (n = 44) | L (n = 37) | P + L (n = 40) | L (n = 44) | |||
Median PFS (95 % CI), months | 24.4 (13.1–35.3) | 8.2 (5.7–12.5) | 16.1 (11–NE) | 10.9 (3.5–16.6) | ||
HR (95 % CI) | 0.341 (0.194–0.599) | 0.539 (0.302–0.962) | ||||
CBR* rate (95 % CI), % | 84.1 (69.9–93.4) | 70.3 (53.0–84.1) | 77.5 (61.5–89.2) | 47.7 (32.5–63.3) | ||
Prior anti-hormone treatment (n = 55) | ||||||
P + L (n = 27) | L (n = 28) | |||||
Median PFS (95 % CI), months | NA | 18.8 (9.7–NE) | 12.9 (2.1–21.8) | |||
HR (95 % CI) | NA | 0.460 (0.222–0.956) | ||||
CBR* rate (95 % CI), % | NA | 77.8 (57.7–91.4) | 53.6 (33.9–72.5) | |||
Disease sitea | Bone-only (n = 29) | Visceral (n = 80) | Other (n = 56) | |||
P + L (n = 17) | L (n = 12) | P + L (n = 37) | L (n = 43) | P + L (n = 30) | L (n = 26) | |
Median PFS (95 % CI), months | NE (9.4–NE) | 13.3 (1.8–NE) | 12.8 (9.7–17.2) | 7.4 (3.7–11.1) | 24.4 (18.1–35.3) | 11.2 (3.5–16.4) |
HR (95 % CI) | 0.294 (0.092–0.945) | 0.547 (0.317–0.944) | 0.402 (0.200–0.808) | |||
CBR* rate (95 % CI), % | 88.2 (63.6–98.5) | 58.3 (27.7–84.8) | 75.5 (58.5–88.2) | 60.5 (44.4–75.0) | 83.3 (65.3–94.4) | 53.8 (33.4–73.4) |